Enhanced Melanoma Vaccine Against Neoantigens and Shared Antigens by CD40 Activation and TLR Agonists

Abstract

This project will test the hypotheses that vaccination with CD40 Ab/TLR3 agonist is safe and induces strong and durable T cell responses to the peptides in the vaccine, and that a mutated neoantigen peptide (BRAF585-614-V600E) is immunogenic. There have been no findings during this reporting period as the study is not yet open at our site.

Open PDF

Document Details

Document Type
Technical Report
Publication Date
Aug 01, 2021
Accession Number
AD1148570

Entities

People

  • Brian Gastman

Tags

Communities of Interest

  • Biomedical

DTIC Thesaurus Topics

  • Abstracts
  • Amino Acids
  • Antibodies
  • Antigens
  • Biomedical Research
  • Cells
  • Clinical Trials
  • Department Of Defense
  • Electronic Mail
  • Information Operations
  • Instructors
  • Lymphocytes
  • Maryland
  • Mass Spectrometry
  • Melanoma
  • Patent Applications
  • Professional Development
  • Technology Transfer
  • Vaccination
  • Vaccines

Fields of Study

  • Biology

Readers

  • Neuroscience
  • Oncology

Technology Areas

  • Biotechnology
  • Biotechnology - Cancer Biotech